Nuvectis (NVCT): Price-to-Revenue Ratio

Brandmark of Nuvectis Pharma, Inc (NVCT)

Nuvectis Pharma, Inc. (NVCT) attracts leading scientists through high autonomy and ambitious R&D goals. The company's price-to-sales ratio confirms this trajectory, where the current status equals . Environmental policy is based on the principles of "green chemistry" and safe disposal. Since there are no commercial products, the financial position relies exclusively on the external raising of investment capital.

NVCT Nuvectis Pharma, Inc. P/S Multiple (07/04/2022 - 11/15/2026)

Nuvectis Pharma, Inc. (NVCT) - metric breakdowns and financial figures

- current quotes and average value forecast:
Market Price Nuvectis Pharma Inc.|NVCT - Price Target Chart
- stock exchange capitalization data:
Market Value Nuvectis Pharma|NVCT - Total Company Value
- issuer book value statistics:
Net Asset Value per Share Nuvectis Pharma|NVCT - Book Capitalization|Market Value to Equity Ratio nuvectis.com|NVCT - Cumulative Company Assets
- issuer credit burden and liquidity indicators:
Debt to Capital Nuvectis Pharma, Inc.|NVCT - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Nuvectis Pharma|NVCT - Company Total Debt|Debt to Book Capital Nuvectis Pharma, Inc|NVCT - Company Long-Term Debts|Company Short-Term Loans and Borrowings Nuvectis Pharma|Immediate Liquidity nuvectis.com
- earnings and multiples data:
NVCT - Company Net Income|Expected Net Income Nuvectis Pharma, Inc.|NVCT - P/E Multiple|Forward P/E Multiple Nuvectis Pharma, Inc|NVCT - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio Nuvectis Pharma, Inc.|NVCT - Operating profit before deduction of amortization|Net earnings per one share for the last twelve months Nuvectis Pharma|NVCT - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months nuvectis.com|NVCT - Net earnings per share growth this year|Earnings growth forecast for next year Nuvectis Pharma, Inc.
- issuer revenue and sales details:
NVCT - Company Sales|Company Projected Revenue Nuvectis Pharma|NVCT - P/S Multiple|Market Cap to Future Revenue Ratio Nuvectis Pharma, Inc
Summary company analytics:Nuvectis Pharma
Mass-produced product of Nuvectis Pharma, Inc

The scale of Nuvectis Pharma, Inc. (NVCT) business and the market recognition of its developments are clearly reflected in this market cap-to-revenue ratio. This multiple compares the total asset value with annual sales volume, determining the innovation premium within an independent product cycle, where stable demand for pharmaceuticals makes this indicator a key measure of the company's fundamental stability and investment potential.

Competing companies

INCY - Price to Sales|Price-to-Revenue Ratio hutch-med.com HCM|Nuvation Corp - Price-to-Revenue Ratio|DAWN - Price-to-Revenue Ratio|Price to Sales Monopar Therapeutics|INBX: P/S Multiple|Price-to-Revenue Multiple I-Mab IMAB|Market Cap to Revenue FENC|Price to Sales Heron Therapeutics, Inc. HRTX|Market Cap to Revenue CHRS (Coherus BioSciences, Inc)|CRBP (Corbus Pharmaceuticals Holdings) - Market Capitalization-to-Revenue Ratio|Cardiff Oncology - Market Cap to Revenue|Market Cap to Sales Volume BYSI (BeyondSpring)|BioAtla - P/S Multiple|Market Capitalization-to-Revenue Ratio LIXT (Lixte Biotechnology Holdings)|CTXR: P/S Multiple|Price to Sales cellectar.com (CLRB)|Price-to-Revenue Ratio BioLineRx|CANF: Market Capitalization-to-Revenue Ratio|P/S Multiple APRE|P/S Multiple Kazia Therapeutics Ltd (KZIA)|Price-to-Revenue Ratio Silexion Therapeutics Corp. SLXN|NCNA (nucana.com) - Price-to-Sales Ratio|CMRX: Market Cap to Revenue|Price to Sales Cyclacel|GTHX: P/S Multiple|Kronos Bio Corporation (KRON) - P/S Multiple|KTRA (kintara.com) - P/S Multiple|Market Cap to Revenue Ratio ONCT (Oncternal Therapeutics)|Price-to-Revenue Ratio Portage Biotech (PRTG)